Source: International Congress 2018 – Lung cancer: personalised medicine
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
P. Zarogoulidis (Thessaloniki, Greece), D. Tsiouda (Thessaloniki, Greece), A. Kallianos (AthensaathenaThessaloniki, Greece), A. Rapti (AthensAthensaathenaThessaloniki, Greece), C. Sardeli (AThessalonikithensAthensaathenaThessaloniki, Greece), H. Huang (ShanghaiAThessalonikithensAthensaathenaThessaloniki, China), W. Hohenforst-Schmidt (HofShanghaiAThessalonikithensAthensaathenaThessaloniki, Germany), G. Trakada (AthensHofShanghaiAThessalonikithensAthensaathenaThessaloniki, Greece), K. Sapalidis (ThessalonikiAthensHofShanghaiAThessalonikithensAthensaathenaThessaloniki, Greece). Inhaled immunotherapy for lung cancer? Certainly possible.. 2220

Member's Comments

No comment yet.

Related content which might interest you: Current place and future of immunotherapy in lung cancer Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016 Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 New evidence on the chemoprevention of inhaled steroids and the risk of lung cancer in COPD Source: Eur Respir J, 53 (6) 1900717; 10.1183/13993003.00717-2019 Year: 2019 Inhaled corticosteroid use and the incidence of lung cancer in COPD Source: Eur Respir J, 55 (2) 1901720; 10.1183/13993003.01720-2019 Year: 2020 Are biphosphonates efficient in the adjuvant treatment of lung cancer? Source: Eur Respir J 2006; 28: Suppl. 50, 754s Year: 2006 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Boosting immunotherapy in lung cancer  Source: International Congress 2017 – ME9 Boosting immunotherapy in lung cancer Year: 2017 Inhaled corticosteroids attenuate epithelial mesenchymal transition: implications for COPD and lung cancer prophylaxis Source: Eur Respir J, 54 (1) 1900778; 10.1183/13993003.00778-2019 Year: 2019 Re-challenge of immunotherapy in a lung cancer patient Source: Virtual Congress 2021 – Lung cancer grand round Year: 2021 Why can initial treatment of localised lung cancer fail? Source: Annual Congress 2007 - Recurrence of lung cancer following resection with curative intent Year: 2007 Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009 Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer? Source: Eur Respir J 2003; 22: 535-541 Year: 2003 Stem cells and lung cancer treatment: any hope? Source: International Congress 2016 – Molecular footprints in lung cancer diagnosis and management Year: 2016 Impact of antibiotics on immunotherapy response in lung cancer patients Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Lung cancer immunotherapy Source: International Congress 2018 – Imminent global problems in lung cancer require joint action: time for an international alliance! Year: 2018 Targeted therapy for lung cancer Source: Eur Respir J 2015; 46: 1239-1241 Year: 2015 ALK- and ROS-1-inhibition: a relevant treatment strategy for lung cancer? Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014